N(4)-acetylsulfamerazine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 67181 |
| CHEMBL ID | 1559815 |
| SCHEMBL ID | 13409107 |
| MeSH ID | M0114440 |
| Synonym |
|---|
| OPREA1_038070 |
| n-[4-(4-methyl-pyrimidin-2-ylsulfamoyl)-phenyl]-acetamide |
| MLS001205096 |
| smr000516270 |
| acetylsulfamerazine |
| OPREA1_673806 |
| STK061358 |
| n-{4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl}acetamide |
| 127-73-1 |
| n-[4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl]acetamide |
| AKOS000715058 |
| FT-0661366 |
| NCGC00245253-01 |
| s0d41hx8kg , |
| unii-s0d41hx8kg |
| n-(4-(((4-methyl-2-pyrimidinyl)amino)sulphonyl)phenyl)acetamide |
| n(4)-acetylsulfamerazine |
| einecs 204-861-5 |
| HMS2829A16 |
| n-(4-(n-(4-methylpyrimidin-2-yl)sulfamoyl)phenyl)acetamide |
| F0914-3223 |
| n4-acetylsulfamerazine |
| n-acetylsulfamerazine |
| sulfamelazine |
| CHEMBL1559815 |
| SCHEMBL13409107 |
| DTXSID40155361 |
| acetamide, n-(4-(((4-methyl-2-pyrimidinyl)amino)sulfonyl)phenyl)- |
| J-005535 |
| SR-01000451152-1 |
| sr-01000451152 |
| 4-acetamido-n-[4-methyl-2-pyrimidinyl]benzene-sulfonamide |
| n4-acetyl-sulfamerazine |
| 4'-((4-methyl-2-pyrimidinyl)sulfamoyl)acetanilide |
| acetanilide, 4'-((4-methyl-2-pyrimidinyl)sulfamoyl)- |
| SB57881 |
| EN300-240157 |
| acetamide, n-[4-[[(4-methyl-2-pyrimidinyl)amino]sulfonyl]phenyl]- |
| sulfamerazine-n-acetyl |
| Excerpt | Reference | Relevance |
|---|---|---|
| "For the following compounds: sulfamerazine, 4- hydroxysulfamerazine , N4- acetylsulfamerazine , N4-acetyl-4- hydroxysulfamerazine , the following data are reported: biosynthesis in the dog, isolation, identification by MS and NMR, TLC (Rf values) and HPLC (capacity factors and molar extinction), half-life of elimination, metabolism, renal excretion and protein binding in dog." | ( Isolation and identification of 4-hydroxysulfamerazine and preliminary studies on its pharmacokinetics in dogs. Hekster, YA; Nouws, JF; Tijhuis, MW; Vree, TB, 1984) | 0.27 |
| " The half-life of elimination of sulphamerazine is 12 h in 'fast' and 24 h in 'slow' acetylators." | ( Pharmacokinetics, acetylation-deacetylation, renal clearance, and protein binding of sulphamerazine, N4-acetylsulphamerazine, and N4-trideuteroacetylsulphamerazine in 'fast' and 'slow' acetylators. Baakman, M; Hekster, CA; Janssen, T; Oosterbaan, M; Termond, E; Tijhuis, M; Vree, TB, ) | 0.13 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 35.4813 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| TDP1 protein | Homo sapiens (human) | Potency | 6.5131 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 39.8107 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 79.4328 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 1.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 1.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 1.0000 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| geminin | Homo sapiens (human) | Potency | 2.3109 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.94) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||